Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

Madhi, SA; Kwatra, G; Richardson, SI; Koen, AL; Baillie, V; Cutland, CL; Fairlie, L; Padayachee, SD; Dheda, K; Barnabas, SL; Bhorat, QE; Briner, C; Ahmed, K; Aley, PK; Bhikha, S; Bhorat, AE; Esmail, A; Horne, E; Kaldine, H; Mukendi, CK; Madzorera, VS; Manamela, NP; Masilela, M; Hermanus, ST; Motlou, T; Mzindle, N; Oelofse, S; Patel, F; Rhead, S; Rossouw, L; Taoushanis, C; van Eck, S; Lambe, T; Gilbert, SC; Pollard, AJ; Moore, PL; Izu, A

COVID-19 Collection

Journal article

Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial

Abstract:: Background COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before vaccination with the ChAdOx-nCoV19 (AZD1222) vaccine on antibody responses through to 180 days.

Methods We did an unmasked post-hoc immunogenicity analysis after the first and second doses of AZD1222 in a randomised, placebo-controlled, phase 1b–2a study done in seven lo...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Madhi, S. A., Kwatra, G., Richardson, S. I., Koen, A. L., Baillie, V., Cutland, C. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Ahmed, K., Aley, P. K., Bhikha, S., Bhorat, A. E., Esmail, A., Horne, E., Kaldine, H., … Izu, A. (2022). Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial. The Lancet Infectious Diseases, 23(3), 295–306.

MLA Style

Madhi, SA, et al. “Durability of ChAdOx1 NCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity against Variants Including Omicron BA.1 and BA.4 6 Months after Vaccination (COV005): a Post-Hoc Analysis of a Randomised, Phase 1b–2a Trial.” The Lancet Infectious Diseases, vol. 23, no. 3, 2022, pp. 295–306.

Chicago Style

Madhi, SA, G Kwatra, SI Richardson, et al. 2022. “Durability of ChAdOx1 NCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity against Variants Including Omicron BA.1 and BA.4 6 Months after Vaccination (COV005): a Post-Hoc Analysis of a Randomised, Phase 1b–2a Trial.” The Lancet Infectious Diseases 23 (3): 295–306.
Print